How Breakthroughs in Immunotherapy are Helping Non-Small Cell Lung Cancer Patients Live Longer
Ed hates cancer and he’ll tell you as much. He was diagnosed with non-small cell lung cancer, the same disease that took his mother. At the time he was diagnosed, Ed’s cancer had advanced to stage 3. From the moment he discovered he had cancer Ed knew he needed to go beyond traditional treatments to beat it. Ed’s oncologist asked him to consider trying IMFINZI (durvalumab). Ed’s cancer has now been eradicated and he believes immunotherapy is opening doors for patients to live longer.
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org
Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.
-
Category
No comments found